What next for rheumatoid arthritis therapy?

Introduction of biological agents for the treatment of the chronic inflammatory joint disease rheumatoid arthritis has reinvigorated research into this debilitating disease. These agents have been shown to both act on the signs and symptoms of disease, as well as retard the progression of joint dest...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in pharmacology Vol. 4; no. 3; pp. 276 - 280
Main Authors Blake, Simon M, Swift, Barbara A
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.06.2004
Subjects
Animals
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - etiology
Cytokines - antagonists & inhibitors
Drug Delivery Systems
Humans
Mice
Mitogen-Activated Protein Kinases - antagonists & inhibitors
IκB
NF-κB
RANKL
IL
PPAR
IKK
MAPK
TNF
RA
Online AccessGet full text

Cover

More Information
Summary:Introduction of biological agents for the treatment of the chronic inflammatory joint disease rheumatoid arthritis has reinvigorated research into this debilitating disease. These agents have been shown to both act on the signs and symptoms of disease, as well as retard the progression of joint destruction. However, these agents are not efficacious in all cases and their expense and route of administration can severely limit their use. Therefore the search continues not only for additional targets to help those individuals refractive to current therapy but also for more affordable orally active small molecule alternatives to biological agents.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1471-4892
1471-4973
DOI:10.1016/j.coph.2004.04.001